insights_auto
Why is DUL up 3.68%?
Dive Deeperchevron_right
DUL:FRA
Alnylam Pharmaceuticals, Inc.
€207.10
arrow_upward
+3.68%(+7.35) 1D
Oct 9, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
€199.70
High
€207.20
Low
€198.05
Mkt. cap
31.13B
Avg. vol.
35.00
Volume
0.00
52-wk high
€423.00
52-wk low
€173.50
No. of employees
2K
Open
€199.70
High
€207.20
Low
€198.05
Mkt. cap
31.13B
Avg. vol.
35.00
Volume
0.00
52-wk high
€423.00
52-wk low
€173.50
No. of employees
2K
News stories
From web sources and news partners
The Motley Fool
·
6 hours ago
Alnylam vs. Ionis: Here's the Better Bad-News Buy
ChartMill
·
2 days ago
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Decent Value Stock Balancing Undervaluation and Growth
AD HOC NEWS
·
2 days ago
Alnylam Pharmaceuticals stock gets a Strong Buy upgrade from Zacks Research
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.